Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PR 15

Drug Profile

PR 15

Alternative Names: Dimeric glycoprotein VI-Fc; GPVI-Fc; PR-15; Revacept

Latest Information Update: 12 Apr 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Corimmun
  • Developer advanceCor
  • Class Antiarrhythmics; Antiplatelets; Antithrombotics; Heart failure therapies; Imaging agents; Platelet membrane glycoproteins; Vascular disorder therapies
  • Mechanism of Action Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute coronary syndromes; Coronary artery disease; Stroke

Most Recent Events

  • 12 Apr 2019 PR 15 is still in phase I trials for Acute coronary syndrome (plaque imaging) in Germany (IV, injection)
  • 13 Dec 2018 Interim adverse events data from a phase II trial in Acute coronary syndromes and Stroke released by AdvanceCor
  • 05 Oct 2018 advanceCor completes a phase II trial in Acute coronary syndromes and Stroke in Germany and United Kingdom (NCT01645306)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top